Niagen Bioscience, Inc. (NAGE) fair value analysis
Nasdaq · Updated 2026-08-24
Forward Fair Value verdict
Fairly valuedBased on TickrTrends' weekly Forward Fair Value model, NAGE is trading at within about 10% of estimated fair value.
- Last price
- $3.53
- Sector
- Healthcare
- 12-month range
- $3.33–$9.88
What our data shows for NAGE
- Our model validated 7 trailing price-to-earnings windows for NAGE, built from quarterly earnings records.
- Shares are trading in the lower third of their 12-month price range of $3.33–$9.88.
- The 14-day relative strength index sits at a neutral 48.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for NAGE
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
How Forward Fair Value works
TickrTrends computes a Forward Fair Value for every covered stock each week: a conservatively normalized historical price-to-earnings multiple is applied to the analyst-consensus earnings estimate for the next full fiscal year. Every input window is validated for continuity and every result is screened for plausibility before publication.